LGBT+ People’s Health Status and Access to Care
This report, based on a nationally representative 2022 KFF survey, provides an analysis of the health experiences of self-identified LGBT+ adults in the U.S. compared to their non-LGBT+ counterparts.
Home Women's Health Policy Program
View the Latest: Women's Health Policy
Filter
-
-
A National Survey of OBGYNs’ Experiences After Dobbs
ReportThis report, based on a nationally representative survey of office-based OBGYNs practicing in the United States, examines the provision of sexual and reproductive health care provided by OBGYNs before and after the Dobbs decision, comparing the experiences of OBGYNs practicing in states where abortion is fully banned, states with gestational restrictions, and states where abortion remains available under most circumstances.
-
Postpartum Individuals Are at Risk of Losing Medicaid During the Unwinding of the Medicaid Continuous Enrollment Provision, Especially in Certain States
Policy WatchThis policy watch discusses Medicaid unwinding and how enrollees who qualified for Medicaid through the pregnancy pathway are at risk of losing Medicaid coverage, particularly those living in states who have not implemented Medicaid expansion and have not extended postpartum Medicaid coverage.
-
Rebuilding the Title X Network Under the Biden Administration
Issue BriefThis issue brief examines what has happened to the Title X network under the Biden Administration regulations, including the number of clinics that have returned to the network, new funding, and how state policies that prohibit pregnancy options counseling that includes abortion and referrals may impact grantees' participation in the Title X program.
-
Update on the Status of Medication Abortion and the Courts
Policy WatchThis policy watch explains the April 21, 2023 United States Supreme Court's ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA's approval of mifepristone, the medication abortion pill.
-
Q & A: Implications of Two Conflicting Federal Court Rulings on the Availability of Medication Abortion and the FDA’s Authority to Regulate Drugs
Policy WatchThis policy watch explains the two conflicting rulings on the provision of mifepristone issued by two separate District Courts on April 7, 2023, Alliance for Hippocratic Medicine v. FDA and State of Washington v. United States Food and Drug Administration.
-
Q&A: Implications of the Ruling on the ACA’s Preventive Services Requirement
Policy WatchThis post summarizes some of the key issues related to the U.S. District Court's March 30 ruling in Braidwood Management v. Becerra, which imposes new limits on the government's ability to enforce preventive service requirements nationwide.
-
Who Uses Telecontraception and Why? A Closer Look at Clients of Four Telecontraception Companies
Issue BriefBased on the findings of a nonprobability sample of 6,000 survey respondents from four telecontraception companies, this brief presents a snapshot of telecontraception users and their reasons for using these platforms.
-
Legal Challenges to the FDA Approval of Medication Abortion Pills
Issue BriefThis issue brief details the Alliance of Hippocratic Medicine challenge to the FDA's approval of the abortion pill, mifepristone. It provides context for the challenge, as well as what some of the possible rulings in the case could mean for access to medication abortion.
-
Women’s Experiences with Provider Communication and Interactions in Health Care Settings: Findings from the 2022 KFF Women’s Health Survey
Issue BriefThis brief presents findings from the 2022 KFF Women’s Health Survey (WHS) on women’s experiences with the health care system including screening for social determinants of health, provider communication and interactions, and discrimination.